Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes

Biomaterials

Volumn 32, Issue 6, 2011, Pages 1715-1723

  Erikçi, Erdem ^a,b   Gursel, Mayda ^a   Gürsel, Ihsan ^a  

^a BILKENT UNIVERSITY   (Turkey)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

CpG DNA; Immune response; Liposomes; Nanotechnology; TLR; Vaccine

Indexed keywords

ANTIGEN PRESENTING CELLS; CHEMOKINES; CLINICAL APPLICATION; CPG DNA; CPG-ODN; CYTOKINE PRODUCTION; CYTOKINES; ENCAPSULATION EFFICIENCY; ENDOSOMES; EX-VIVO; GENE TRANSCRIPTS; IMMUNE ACTIVATION; IMMUNE CELLS; IMMUNE RESPONSE; IMMUNOGENICITY; IN-VITRO; IN-VIVO; INFECTIOUS DISEASE; NANOLIPOSOMES; OLIGODEOXYNUCLEOTIDES; OVALBUMINS; PHYSICOCHEMICAL PROPERTY; PROTEIN ANTIGENS; STAND -ALONE; SURFACE MARKERS; THERAPEUTIC VACCINES; TLR;

ANTIGENS; DNA; IMMUNOLOGY; LIPOSOMES; NANOTECHNOLOGY; PHOSPHOLIPIDS; VACCINES;

ENCAPSULATION;

CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; LIPOSOME; OVALBUMIN; TOLL LIKE RECEPTOR 9; VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; ENCAPSULATION; ENDOSOME; FEMALE; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; MALE; MOUSE; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TH1 CELL; UPREGULATION;

ANIMALS; ANTIGENS, CD40; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-18; INTERLEUKIN-6; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOSTRUCTURES; OLIGODEOXYRIBONUCLEOTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN;

EID: 78650305541     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.054     Document Type: Article

References (38)

1. Medzhitov R., Janeway C.A. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998, 10(5):351-353.
2. Takeshita F., Gursel I., Ishii K.J., Suzuki K., Gursel M., Klinman D.M. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 2004, 16(1):17-22.
3. Takeda K., Kaisho T., Akira S. Toll-like receptors. Ann Rev Immunol 2003, 21:335-376.
4. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4(7):499-511.
5. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002, 168(2):554-561.
6. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 2007, 19(1):39-45.
7. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440(7085):808-812.
8. Palm N.W., Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009, 227(1):221-233.
9. Pasare C., Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbe Infect 2004, 6(15):1382-1387.
10. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813):740-745.
11. Takeshita F., Leifer C.A., Gursel I., Ishii K.J., Takeshita S., Gursel M., et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001, 167(7):3555-3558.
12. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413(6857):732-738.
13. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303(5663):1526-1529.
14. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5(10):987-995.
15. Gursel M., Verthelyi D., Gursel I., Ishii K.J., Klinman D.M. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 2002, 71(5):813-820.
16. Kerkmann M., Rothenfusser S., Hornung V., Towarowski A., Wagner M., Sarris A., et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003, 170(9):4465-4474.
17. Gursel M., Gursel I., Mostowski H.S., Klinman D.M. CXCL16 influences the nature and specificity of CpG-induced immune activation. J Immunol 2006, 177(3):1575-1580.
18. Honda K., Ohba Y., Yanai H., Negishi H., Mizutani T., Takaoka A., et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005, 434(7036):1035-1040.
19. Klinman D.M., Currie D., Gursel I., Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004, 199:201-216.
20. Barry M.E., Pinto-Gonzalez D., Orson F.M., McKenzie G.J., Petry G.R., Barry M.A. Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum Gene Ther 1999, 10(15):2461-2480.
21. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4(2):145-160.
22. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci (USA) 1991, 88(24):11460-11464.
23. Gursel I., Gursel M., Ishii K.J., Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001, 167(6):3324-3328.
24. Tanaka T., Hu-Li J., Seder R.A., Fazekas de St Groth B., Paul W.E. Interleukin 4 suppresses interleukin 2 and interferon gamma production by naive T cells stimulated by accessory cell-dependent receptor engagement. Proc Natl Acad Sci (USA) 1993, 90(13):5914-5918.
25. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Ann Rev Immunol 2005, 23:515-548.
26. Abbas A.K., Lichtman A.H., Pillai S. Cellular and molecular Immunology 2007, Saunders Elsevier, Philadelphia. 6th ed.
27. Fenske D.B., MacLachlan I., Cullis P.R. Long-circulating vectors for the systemic delivery of genes. Curr Opin Mol Ther 2001, 3(2):153-158.
28. Mutwiri G.K., Nichani A.K., Babiuk S., Babiuk L.A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Contr Rel 2004, 97(1):1-17.
29. Dinarello C.A., Fantuzzi G. Interleukin-18 and host defense against infection. J Infect Dis 2003, 187(Suppl. 2):S370-S384.
30. Srinivasan A., Salazar-Gonzalez R.M., Jarcho M., Sandau M.M., Lefrancois L., McSorley S.J. Innate immune activation of CD4 T cells in salmonella-infected mice is dependent on IL-18. J Immunol 2007, 178(10):6342-6349.
31. French A.R., Holroyd E.B., Yang L., Kim S., Yokoyama W.M. IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. Cytokine 2006, 35(5-6):229-234.
32. Iwai Y., Hemmi H., Mizenina O., Kuroda S., Suda K., Steinman R.M. An IFN-gamma-IL-18 signaling loop accelerates memory CD8+ T cell proliferation. PLOS One 2008, 3(6). e2404.
33. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448(7152):501-505.
34. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458(7237):514-518.
35. Janeway C.A., Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998, 10(5):349-350.
36. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003, 2(9):727-735.
37. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11(4 Suppl):S63-S68.
38. Joseph A., Louria-Hayon I., Plis-Finarov A., Zeira E., Zakay-Rones Z., Raz E., et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002, 20(27-28):3342-3354.